BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Illinois, Chicago, Illinois, United States
Contact: Study coordinator (Abiola R Ibreeheem, MD) · abiolai@uic.edu · 312-413-1581
Contact: Study coordinator (Prathmika Jha, BS) · pjha7@uic.edu · 312-413-2746

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

HER2 Low Breast Carcinoma · Triple Negative Breast Cancer · Hormone-receptor-positive Breast Cancer

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Hormon Receptor Positive Breast Cancer · Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Dessau, Germany · Alicante, Spain

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

HR+/HER2+ Early Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Nanjing, China · Hangzhou, China